Capital Research Global Investors 13D/13G Filings for Quince Therapeutics, Inc. (QNCX)

Capital Research Global Investors 13D and 13G filings for Quince Therapeutics, Inc.:

  • Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
  • Shares have been adjusted for stock splits.
Time period
Reported
DateTime
Transaction
Date
Type Company
Symbol
Filed By
Symbol
Shares Owned
% Owned
Shares Vs. Prev Report View
2022-02-11
12:22 pm
Sale
2022-02-14 13G Quince Therapeutics, Inc.
QNCX
Capital Research Global Investors 0
0.000%
-2,605,753decrease
(Position Closed)
Filing
2021-02-16
1:16 pm
Purchase
2021-02-16 13G Quince Therapeutics, Inc.
QNCX
Capital Research Global Investors 2,605,753
8.800%
162,839increase
(+6.67%)
Filing